Propanc Biopharma plans Phase 1b cancer drug trial for February 2027

September 9, 2026 8:30 AM

Propanc Biopharma, Inc. (Nasdaq: PPCB) announced plans to begin a Phase 1b first-in-human study of its drug candidate PRP in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found